Neuburgh Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Neuburgh Advisers’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$122K	Hold	2,512	–	–	﹤0.01%	773
2019 Q2	$132K	Sell	2,512 -368	-13%	-$21.1K	﹤0.01%	764
2019 Q1	$152K	Sell	2,880 -2,080	-42%	-$102K	0.01%	725
2018 Q4	$204K	Buy	+4,960	New	+$186K	0.01%	630
2018 Q3	–	Sell	-704	Closed	-$32K	–	909
2018 Q2	$32K	Buy	+704	New	+$32.1K	﹤0.01%	861

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Neuburgh Advisers's GBT Position: Q3 2019 in Review

Neuburgh Advisers held its Global Blood Therapeutics, Inc. (GBT) position steady in Q3 2019 at 2,512 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Neuburgh Advisers first reported a position in GBT in Q2 2018 and has held it in 5 quarters since. The position peaked at $204K in Q4 2018. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

Neuburgh Advisers held 2,512 shares of Global Blood Therapeutics, Inc. worth $122K as of Q3 2019.
Neuburgh Advisers left its Global Blood Therapeutics, Inc. share count unchanged in Q3 2019.
Global Blood Therapeutics, Inc. made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #773 holding.
Neuburgh Advisers first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and has held it in 5 quarters since.
Neuburgh Advisers's Global Blood Therapeutics, Inc. position peaked at $204K in Q4 2018.
208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.